Just published in JACC CardioOncology!!
Mitigation of Doxorubicin Cardiotoxicity With Synergistic miRNA Combinations Identified Using Combinatorial Genetics en masse (CombiGEM)
Combinatorial miRNAs for Doxorubicin Cardiotoxicity
Anthracycline chemotherapeutics for cancer such as doxorubicin cause cardiomyocyte loss and heart failure. Therapeutics that prevent doxorubicin-induced cardiomyopathy are urgently needed. In this study, we identified a microRNA combination that synergistically and potently protects against doxorubicin cardiotoxicity, by using a novel phenotypic screening technology, CombiGEM. https://www.jacc.org/doi/10.1016/j.jaccao.2025.03.007
Yasutomi Higashikuni, M.D., Ph.D., FESC
Associate Professor of Cardiovascular Medicine
My research interests include homeostatic inflammation, RNA metabolism and modification, and synthetic biology.